Cargando…

Why we do what we do. A brief analysis of cancer therapies

The goal of all medical activity is to preserve health in fit people, and to restore the sick into a state of complete physical, mental and social wellbeing. In an effort to determine whether we are achieving this last goal in oncology, herein we review the biological and clinical framework that has...

Descripción completa

Detalles Bibliográficos
Autor principal: Galmarini, Carlos M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Leibniz Research Centre for Working Environment and Human Factors 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726489/
https://www.ncbi.nlm.nih.gov/pubmed/33312104
http://dx.doi.org/10.17179/excli2020-2972
_version_ 1783620900011114496
author Galmarini, Carlos M.
author_facet Galmarini, Carlos M.
author_sort Galmarini, Carlos M.
collection PubMed
description The goal of all medical activity is to preserve health in fit people, and to restore the sick into a state of complete physical, mental and social wellbeing. In an effort to determine whether we are achieving this last goal in oncology, herein we review the biological and clinical framework that has led to the foundations of the current anticancer treatment paradigm. Currently, cancer therapy is still based on the ancient axiom that states that the complete eradication of the tumor burden is the only way to achieve a cure. This strategy has led to a substantial improvement in survival rates as cancer mortality rates have dropped in an unprecedented way. Despite this progress, more than 9 million people still die from cancer every year, indicating that the current treatment strategy is not leading to a cancer cure, but to a cancer remission, that is “the temporary absence of manifestations of a particular disease”; after months or years of remission, in most patients, cancer will inevitably recur. Our critical analysis indicates that it is time to discuss about the new key challenges and future directions in clinical oncology. We need to generate novel treatment strategies more suited to the current clinical reality.
format Online
Article
Text
id pubmed-7726489
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Leibniz Research Centre for Working Environment and Human Factors
record_format MEDLINE/PubMed
spelling pubmed-77264892020-12-10 Why we do what we do. A brief analysis of cancer therapies Galmarini, Carlos M. EXCLI J Review Article The goal of all medical activity is to preserve health in fit people, and to restore the sick into a state of complete physical, mental and social wellbeing. In an effort to determine whether we are achieving this last goal in oncology, herein we review the biological and clinical framework that has led to the foundations of the current anticancer treatment paradigm. Currently, cancer therapy is still based on the ancient axiom that states that the complete eradication of the tumor burden is the only way to achieve a cure. This strategy has led to a substantial improvement in survival rates as cancer mortality rates have dropped in an unprecedented way. Despite this progress, more than 9 million people still die from cancer every year, indicating that the current treatment strategy is not leading to a cancer cure, but to a cancer remission, that is “the temporary absence of manifestations of a particular disease”; after months or years of remission, in most patients, cancer will inevitably recur. Our critical analysis indicates that it is time to discuss about the new key challenges and future directions in clinical oncology. We need to generate novel treatment strategies more suited to the current clinical reality. Leibniz Research Centre for Working Environment and Human Factors 2020-10-28 /pmc/articles/PMC7726489/ /pubmed/33312104 http://dx.doi.org/10.17179/excli2020-2972 Text en Copyright © 2020 Galmarini http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0/) You are free to copy, distribute and transmit the work, provided the original author and source are credited.
spellingShingle Review Article
Galmarini, Carlos M.
Why we do what we do. A brief analysis of cancer therapies
title Why we do what we do. A brief analysis of cancer therapies
title_full Why we do what we do. A brief analysis of cancer therapies
title_fullStr Why we do what we do. A brief analysis of cancer therapies
title_full_unstemmed Why we do what we do. A brief analysis of cancer therapies
title_short Why we do what we do. A brief analysis of cancer therapies
title_sort why we do what we do. a brief analysis of cancer therapies
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726489/
https://www.ncbi.nlm.nih.gov/pubmed/33312104
http://dx.doi.org/10.17179/excli2020-2972
work_keys_str_mv AT galmarinicarlosm whywedowhatwedoabriefanalysisofcancertherapies